跳至主要内容
临床试验/CTRI/2019/05/019075
CTRI/2019/05/019075已完成未知

â??Oral Acetazolamide for Sodium Valproate induced weight gain in Bipolar Affective Disorder - An open label studyâ??

Dr Mathews Joseph Panicker0 个研究点目标入组 13 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
13

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Out patients or in patients diagnosed as Bipolar Affective Mood Disorder using MINI PLUS and only on Sodium Valproate.
  • -Both males and females
  • -18 â?? 60 years of age
  • -Without any co-morbid psychiatric illness other than nicotine use.

排除标准

  • -Persons on Acetazolamide for any medical reasons.
  • -No known medical conditions in which acetazolamide is contraindicated like hyperchloremic acidosis, hypokalemia, hyponatremia, adrenal insufficiency, impaired kidney function, hypersensitivity to acetazolamide or other sulphonamides, liver diseases.
  • -Pregnancy, lactation
  • -Sub normal intelligence

研究者

发起方
Dr Mathews Joseph Panicker

相似试验